Credit: Canva
Low-dose CT chest scans could help detect pneumonia in at-risk patients while exposing them to only small amounts of radiation, a new study has found. The research, published in Radiology: Cardiothoracic Imaging, shows that ultra-low-dose scans can effectively detect pneumonia in patients with compromised immune systems, enabling doctors to treat the infection before it becomes life-threatening. According to the researchers, these scans expose patients to just 2% of the radiation dose used in a standard CT scan.
"This study paves the way for safer, AI-driven imaging that reduces radiation exposure while preserving diagnostic accuracy,” lead researcher Dr Maximiliano Klug, a radiologist with the Sheba Medical Center in Ramat Gan, Israel, said in a news release. He added that CT scans are the gold standard for detecting pneumonia but there are concerns regarding the risk posed by repeated exposure to radiation. There is a solution- ultra-low-dose CT scan. However, the problem is that these scans can be grainy and hard to read, researchers said.
Study Gives Solution To This
To overcome that, Klug's team developed an AI program that could help "de-noise" low-dose scans, making them sharper and easier to read. Between September 2020 and December 2022, 54 patients with compromised immune systems who had fevers underwent a pair of chest CT scans -- a normal dose scan and an ultra-low-dose scan. The AI program cleaned up the low-dose scan, and then both sets of images were given to a pair of radiologists for assessment. Radiologists had 100% accuracy in detecting pneumonia and other lung problems with the AI-cleaned low-dose scans, but 91% to 98% accuracy in examining the scans that hadn’t been improved through AI, results show.
"This pilot study identified infection with a fraction of the radiation dose," Klug said. "This approach could drive larger studies and ultimately reshape clinical guidelines, making denoised ultra-low dose CT the new standard for young immunocompromised patients.
How Can You Detect Pneumonia?
Pneumonia is a lung infection that causes the air sacs in the lungs to fill with fluid or pus and can be caused by bacteria, viruses, or fungi. The symptoms can range from milk to severe, which includes:
Coughing with or without cough
Fever
Chills
Trouble breathing
Chest pain, especially when breathing deeply or coughing
Sweating or chills
Rapid heart rate
Loss of appetite
Bluish skin, lips, and nails
Confusion.
How to detect Pneumonia in coughing newborns and toddlers?
Pneumonia can severely affect newborns and young children as their lungs are comparatively more sensitive. As per Dr Goyal, young children can cough for various reasons including seasonal infections and tonsillitis, which is very common in this age group. But if they look visibly irritable and have poor sleep patterns, then parents must reach out to an expert. "I am not saying that parents must visit a hospital but any local paediatrician would be able to detect pneumonia in your kid.
Credit: iStock
Aedes aegypti mosquitoes that spread dengue, chikungunya and Zika are showing resistance to permethrin, a commonly used pyrethroid insecticide, in parts of Pune, according to a new ICMR-National Institute of Virology (NIV) study.
The finding, published as preprint in the International Journal of Tropical Insect Science, raises concerns about the effectiveness of insecticide-based mosquito control, particularly during outbreaks.
Researchers collected Aedes aegypti mosquitoes from nine Pune Municipal Corporation wards — Pashan, Susgaon, Khadki, Yerawada, Warje, Hadapsar, Kondhwa, Kothrud and Dhankawdi — between February and May 2024.
They exposed the mosquitoes to 0.75% permethrin, the standard dose used in WHO susceptibility testing.
Resistance was detected in mosquitoes from six of the nine localities, while mosquitoes from three wards remained susceptible.
The researchers then used PCR amplification and Sanger sequencing to look for genetic changes associated with pyrethroid resistance.
They identified four previously reported mutations:
The D1763Y mutation, which can occur alongside V1016G, was not detected. The differences in mutations across wards suggest that resistance mechanisms may vary between mosquito populations.
Pyrethroid resistance can develop through metabolic changes, target-site mutations, or both. Target-site changes, known as knockdown resistance (kdr) mutations, can reduce the ability of pyrethroids to act on the mosquito's voltage-gated sodium channel.
Pyrethroids have been widely used in India for mosquito control since the 1980s. Reduced susceptibility to deltamethrin, lambda-cyhalothrin and permethrin has also been reported in several states, including Assam, Delhi, West Bengal and Rajasthan.
The researchers noted that the widespread use of pyrethroid-based household mosquito-control products, including vaporizers, mats and coils, could potentially contribute to resistance.
According to the WHO South-East Asia Region Epidemiological Bulletin which reported 22,938 dengue cases in India through June 2026.
When mosquitoes develop resistance, more of them can survive exposure to insecticides that would normally kill susceptible mosquitoes. This could make controlling Aedes aegypti more difficult, particularly during dengue outbreaks.
Importantly, insecticide resistance does not mean the mosquitoes cause more severe dengue. The concern is that commonly used mosquito-control measures may become less effective.
The researchers called for regular resistance surveillance, insecticide rotation and locally tailored integrated vector-management strategies.
The researchers noted that areas reporting more dengue cases may have experienced more frequent insecticide spraying, which could potentially be associated with higher resistance.
However, the study did not directly track insecticide use in these areas and did not establish that spraying caused the resistance.
The researchers stressed the need for continued surveillance to track resistance and adapt mosquito-control strategies to local conditions.
Future research could examine resistance genes through genetic mapping, transcriptomic profiling and CRISPR-Cas9 studies, while studying behavioral changes that may help mosquitoes survive insecticide exposure.
Credit: Wikimedia Commons
Cancer cases linked to the September 11, 2001, World Trade Center terror attacks have surged 75%, according to new research, highlighting the ongoing health crisis even 25 years later.
The research was conducted by Northwell Health’s Long Island Jewish (LIJ) Medical Center, which provides free medical monitoring to people affected by the aftermath of the attacks at New York’s World Trade Center, where nearly 3,000 people were killed.
About two-thirds of all enrollees are certified for at least one WTC-related health condition, while 30% of those enrolled through Northwell have battled cancer. That number is expected to rise dramatically over the next decade.
“For over 25 years, we have cared for people who were exposed to the aftermath of September 11th,” said Jacqueline Moline, director of the Northwell WTC Health Program.
“Over 57,000 cases of cancer have been documented, and cancer rates — including rare cancers — are rising. There has been a two-fold increase in lung cancer in just five years. Our fear is that cancer diagnoses will only rise as we move into the next 25 years.”
Northwell’s WTC Health Program saw 9/11-certified cancer cases increase from 177 in 2023 to 235 in 2025 — a 75% jump over three years.
Another 132 new cases were reported through the first half of 2026, continuing the trend. That brings the total to 811 new cases over 42 months.
Prostate and skin cancers were the most common, followed by breast and urinary tract cancers.
By comparison, the program recorded 1,634 cancer cases during the first decade from 2013 to 2022, and 2,445 all-time cases through June among 1,489 people.
Crisis Grows From Lung Diseases To Cancer
Researchers at the center noted that September 11 was not a one-day event. The toxic dust cloud at Ground Zero and the gruelling recovery work created a persistent environmental catastrophe that continues to affect lives.
A variety of lung diseases were seen earlier among those affected. Now, after a decades-long incubation, a range of cancers is emerging as a growing concern.
"Hundreds of thousands of people were at risk then and remain at risk for disease now. While we initially saw respiratory disease, we now are faced with increasing numbers of our patients developing cancer," Moline said.
Further, a trove of newly released files by New York City Mayor Zohran Mamdani indicates that toxic air persisted for months after the 9/11 attacks on the World Trade Center and that officials played down the health risks.
“People got sick because the leaders they trusted lied and told them they were safe to breathe in toxic air,” Mamdani said at a news conference with survivors.
“As the years pass and the human toll grows, we reckon with the cost of September 11th whenever another New Yorker is stolen from us too soon. Now, close to 25 years later, more people have died from 9/11-related illnesses than were killed on the day itself.
Credit: iStock
Google DeepMind has launched AlphaGenome Atlas, an AI-powered database that maps the predicted effects of all 9 billion possible single-letter changes in the human genome.
The novel tool could help scientists identify genetic changes linked to rare diseases, understand how mutations affect gene function and uncover new clues about human health and disease.
Scientists have a strong understanding of the roughly 2% of the genome that codes for proteins. But interpreting mutations in the remaining 98% of non-coding regulatory DNA has been much more difficult.
Changes in these regions can disrupt how genes are regulated and affect cellular functions. By pre-computing the predicted effects of billions of genetic variations, AlphaGenome Atlas aims to give researchers a map for navigating this largely unexplored part of the genome.
The resource could help researchers investigate unsolved rare diseases, uncover biological mechanisms behind common illnesses and support drug discovery.
Also read:EXCLUSIVE: GLP-1 Drugs Are The ‘New Statins’, Says University Hospital Birmingham Professor
The Atlas introduces the AlphaGenome Variant Impact (AVI) score, a single score that combines predictions for genetic effects across coding and non-coding regions.
This allows researchers to prioritize potentially important variants without having to sift through thousands of individual data points.
Each AVI score is also linked to the biological features contributing to the prediction, including aspects of gene regulation predicted by AlphaGenome and protein-impact information from AlphaMissense.
AlphaGenome Atlas contains predictions for the effects of 9 billion single-nucleotide variants in the human genome.
The dataset is about 1 petabyte in size, making it more than 30 times larger than the previous AlphaFold Database.
The Atlas brings together several resources, including:
Read More: HHS Announces US FDA’s First AI Chief: Here’s What It Means For The Future Of Drug Regulation
One of the biggest challenges in rare disease research is identifying the few potentially causal variants among thousands of genetic changes.
Researchers at the Broad Institute, working with the GREGoR Consortium, used the AVI score to prioritise variants in unsolved rare disease cases and identified a variant affecting the DNM1 gene which is strongly linked to epileptic encephalopathy.
AlphaGenome Atlas is also being used to study rare, non-coding variants linked to complex traits, where the large number of harmless genetic changes can create substantial statistical noise.
Researchers at the University of Exeter applied the Atlas to identify 22% more non-coding genetic associations.
Among the top 1% of variants predicted to have the greatest impact, the analysis identified 19 genetic regions linked to body mass index (BMI), helping direct further targeted research.
Google DeepMind said AlphaGenome Atlas is being made free to the scientific community for academic research, with the aim of opening new pathways for genetic and biomedical discovery.
The company described it as a comprehensive catalogue of how genetic mutations are predicted to affect molecular biology, covering every possible single-letter genetic change across the human genome.
© $2026 Times Horizon Private Limited